Fusion Antibodies (LON:FAB) Shares Down 12.7% – Should You Sell?

Fusion Antibodies plc (LON:FAB) dropped 12.7% on Thursday . The company traded as low as GBX 7.68 ($0.09) and last traded at GBX 7.68 ($0.09). Approximately 1,231,095 shares traded hands during mid-day trading, a decline of 54% from the average daily volume of 2,684,324 shares. The stock had previously closed at GBX 8.80 ($0.11).

Fusion Antibodies Stock Performance

The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40. The company has a 50-day moving average of GBX 6.26 and a 200-day moving average of GBX 4.53. The firm has a market capitalization of £7.74 million, a price-to-earnings ratio of -203.00 and a beta of 0.49.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.